A Prognostic and Predictive Study of BCR-ABL Expression Based on Characterization of Fusion Transcripts

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

Brian Druker, Charles L. Sawyers, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2001 · 2.7K citations · Full text

Medicine, Hematology, Oncology +17

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

J Groffen, John Stephenson, Nora Heisterkamp et al. · Cell · 1984 · 1.6K citations

Life Sciences, Genetics, Hematology +9

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML

Susan Branford, David T Yeung, David M. Ross et al. · Blood · 2013 · 177 citations

Medicine, Molecular Medicine, Molecular Oncology +3

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript

Claire Lucas, Robert J. Harris, Athina Giannoudis et al. · Haematologica · 2009 · 118 citations · Full text

Life Sciences, Hematology, Oncology +14

Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis

Giuseppe Saglio, Fabrizio Pane, Enrico Gottardi et al. · Blood · 1996 · 104 citations · Full text

Life Sciences, Hematology, Molecular Biology +12